Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Moleculin Biotech, Inc. (MBRX) had Income from Continuous Operations of $-25.40M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-25.40M |
|
-- |
|
-- |
|
$5.91M |
|
$-5.91M |
|
$-19.49M |
|
$-25.40M |
|
$-25.40M |
|
$-25.40M |
|
|
Income from Continuous Operations |
$-25.40M |
$-25.40M |
|
$-25.40M |
|
$-5.91M |
|
$-5.88M |
|
37.30M |
|
37.30M |
|
$-0.68 |
|
$-0.68 |
|
| Balance Sheet Financials | |
$7.88M |
|
$0.08M |
|
$12.47M |
|
$20.35M |
|
$5.68M |
|
-- |
|
$41.59M |
|
$47.27M |
|
$-26.92M |
|
$-38.07M |
|
$-26.92M |
|
49.50M |
|
| Cash Flow Statement Financials | |
$-17.37M |
|
-- |
|
$19.80M |
|
$4.28M |
|
$6.70M |
|
$2.42M |
|
$1.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.37M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
94.35% |
|
66.72% |
|
-124.79% |
|
94.35% |
|
$-0.54 |
|
$-0.47 |
|
$-0.47 |
|